Press Releases

MedGenome appoints Michael A. Nemzek as Chief Commercial Officer. The hire is intended to strengthen the company’s commercial strategy and growth.

MedGenome presents tumor microenvironment analysis findings at the AACR Cancer Immunotherapy Conference in New York. The talk highlights the company’s immuno-oncology research.

MedGenome partners with ZellNet Consulting to expand genomics solutions for immune-oncology research. The collaboration pairs genomic and immunological expertise.

MedGenome unveils SAGVDB, a database cataloging genetic variation across South Asian populations. The resource is built to support genetic research specific to the region.

MedGenome opens free access to OncoPeptTOPE™, its proprietary neo-antigen and neo-epitope database. The resource supports ongoing cancer immunotherapy research.

MedGenome’s analysis of Wellderley cohort data surfaces a notable trend in gene mutations linked to cardiac function. The findings add to research on genetic contributors to heart health.

MedGenome presents OncoMD, its genomics data analysis and interpretation platform, for cancer discovery research. The session covers how the platform supports oncology-focused analysis.

MedGenome presents OncoPept, its point solution for cancer immunotherapy, at the Molecular Medicine Tricon 2016. The platform is positioned to help harness the immune system against cancer.

MedGenome’s OncoMD platform is used to analyze genetic alterations in mesothelioma. The work illustrates the platform’s application in a rare and hard-to-treat cancer type.

MedGenome acquires Lifecode Health’s assets, including a CLIA-certified lab in the Bay Area. The acquisition expands the company’s clinical testing footprint in the U.S.